Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies

American Academy of Sleep Medicine practice parameters designate sodium oxybate (SXB) as a standard of care for cataplexy, excessive daytime sleepiness (EDS), and disrupted night‐time sleep in narcolepsy. Recently, a lower‐sodium oxybate (LXB) with 92% less sodium than SXB was approved in the United...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Cuiping, Jenkins, Jack, Zomorodi, Katie, Skowronski, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604214/
https://www.ncbi.nlm.nih.gov/pubmed/34121333
http://dx.doi.org/10.1111/cts.13087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604214/
https://www.ncbi.nlm.nih.gov/pubmed/34121333
http://dx.doi.org/10.1111/cts.13087

Ejemplares similares